Medicare Rx "Non-Interference" Provision Protects Patients, PhRMA CEO Maintains
This article was originally published in The Pink Sheet Daily
Executive Summary
Language in the Medicare prescription drug law that prohibits HHS from "interfering" in drug price negotiations will ensure that patients have more therapeutic options, Pharmaceutical Research & Manufacturers of America CEO Alan Holmer maintained during the trade group's annual meeting in Palm Beach, Fla. April 2.
You may also be interested in...
Medicare Rx "Non-Interference" Provision Is Bipartisan Target, Former CMS Official Says
Statutory language prohibiting HHS from negotiating prices with drug manufacturers will likely be repealed in the next two years regardless of the presidential election's outcome, Patton Boggs partner Kathleen Means says.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.